The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Lopac-B-2292     6-phenylmethoxy-7H-purin-2- amine

Synonyms: PubChem9681, O6-BG, O(6)-Bgua, SureCN61740, CHEMBL407874, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Lopac-B-2292


High impact information on Lopac-B-2292

  • CONCLUSION: We recommend comprehensive clinical toxicologic evaluation of combination therapy with O6-benzylguanine plus BCNU, which would allow subsequent design of phase I clinical trials [6].
  • Applied molecular evolution of O6-benzylguanine-resistant DNA alkyltransferases in human hematopoietic cells [1].
  • O6-Benzylguanine was highly effective in depleting the alkyltransferase activity of cultured human colon tumor (HT29) cells [7].
  • These results indicate that depletion of the alkyltransferase by O6-benzylguanine may be used to investigate the role of the DNA repair protein in carcinogenesis and mutagenesis and that this treatment may be valuable to increase the chemotherapeutic effectiveness of chloroethylating agents [7].
  • We selected for G156A MGMT (triangle upMGMT) transduced LTRC present in 5 x 10(4) to 100 x 10(4) marrow cells infused into nonmyeloablated mice by the administration of O(6)-benzylguanine (BG) and BCNU every 3 to 4 weeks [8].

Chemical compound and disease context of Lopac-B-2292


Biological context of Lopac-B-2292


Anatomical context of Lopac-B-2292


Associations of Lopac-B-2292 with other chemical compounds


Gene context of Lopac-B-2292


Analytical, diagnostic and therapeutic context of Lopac-B-2292


  1. Applied molecular evolution of O6-benzylguanine-resistant DNA alkyltransferases in human hematopoietic cells. Davis, B.M., Encell, L.P., Zielske, S.P., Christians, F.C., Liu, L., Friebert, S.E., Loeb, L.A., Gerson, S.L. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  2. Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU. Gerson, S.L., Phillips, W., Kastan, M., Dumenco, L.L., Donovan, C. Blood (1996) [Pubmed]
  3. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. Friedman, H.S., Kokkinakis, D.M., Pluda, J., Friedman, A.H., Cokgor, I., Haglund, M.M., Ashley, D.M., Rich, J., Dolan, M.E., Pegg, A.E., Moschel, R.C., McLendon, R.E., Kerby, T., Herndon, J.E., Bigner, D.D., Schold, S.C. J. Clin. Oncol. (1998) [Pubmed]
  4. Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Dolan, M.E., Mitchell, R.B., Mummert, C., Moschel, R.C., Pegg, A.E. Cancer Res. (1991) [Pubmed]
  5. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer. Liu, L., Schwartz, S., Davis, B.M., Gerson, S.L. Cancer Res. (2002) [Pubmed]
  6. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. Friedman, H.S., Dolan, M.E., Moschel, R.C., Pegg, A.E., Felker, G.M., Rich, J., Bigner, D.D., Schold, S.C. J. Natl. Cancer Inst. (1992) [Pubmed]
  7. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Dolan, M.E., Moschel, R.C., Pegg, A.E. Proc. Natl. Acad. Sci. U.S.A. (1990) [Pubmed]
  8. Limiting numbers of G156A O(6)-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection. Davis, B.M., Koç, O.N., Gerson, S.L. Blood (2000) [Pubmed]
  9. Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors. Warren, K.E., Aikin, A.A., Libucha, M., Widemann, B.C., Fox, E., Packer, R.J., Balis, F.M. J. Clin. Oncol. (2005) [Pubmed]
  10. A single amino acid change in human O6-alkylguanine-DNA alkyltransferase decreasing sensitivity to inactivation by O6-benzylguanine. Crone, T.M., Pegg, A.E. Cancer Res. (1993) [Pubmed]
  11. Modulation of ethylnitrosourea-induced toxicity and mutagenicity in human cells by O6-benzylguanine. Bronstein, S.M., Hooth, M.J., Swenberg, J.A., Skopek, T.R. Cancer Res. (1992) [Pubmed]
  12. Determinants of O6-alkylguanine-DNA alkyltransferase activity in human colon cancer. Gerson, S.L., Allay, E., Vitantonio, K., Dumenco, L.L. Clin. Cancer Res. (1995) [Pubmed]
  13. Beta-glucuronidase-cleavable prodrugs of O6-benzylguanine and O6-benzyl-2'-deoxyguanosine. Wei, G., Loktionova, N.A., Pegg, A.E., Moschel, R.C. J. Med. Chem. (2005) [Pubmed]
  14. Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate. Berg, S.L., Gerson, S.L., Godwin, K., Cole, D.E., Liu, L., Balis, F.M. Cancer Res. (1995) [Pubmed]
  15. Mutations in human O6-alkylguanine-DNA alkyltransferase imparting resistance to O6-benzylguanine. Crone, T.M., Goodtzova, K., Edara, S., Pegg, A.E. Cancer Res. (1994) [Pubmed]
  16. Point mutations in human O6-alkylguanine-DNA alkyltransferase prevent the sensitization by O6-benzylguanine to killing by N,N'-bis (2-chloroethyl)-N-nitrosourea. Loktionova, N.A., Pegg, A.E. Cancer Res. (1996) [Pubmed]
  17. Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2'-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity. Marathi, U.K., Dolan, M.E., Erickson, L.C. Cancer Res. (1994) [Pubmed]
  18. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Ragg, S., Xu-Welliver, M., Bailey, J., D'Souza, M., Cooper, R., Chandra, S., Seshadri, R., Pegg, A.E., Williams, D.A. Cancer Res. (2000) [Pubmed]
  19. Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy. Nutt, C.L., Noble, M., Chambers, A.F., Cairncross, J.G. Cancer Res. (2000) [Pubmed]
  20. Repair of O6-methylguanine and O4-methylthymidine in F344 rat liver following treatment with 1,2-dimethylhydrazine and O6-benzylguanine. O'Toole, S.M., Pegg, A.E., Swenberg, J.A. Cancer Res. (1993) [Pubmed]
  21. Reaction of O6-benzylguanine-resistant mutants of human O6-alkylguanine-DNA alkyltransferase with O6-benzylguanine in oligodeoxyribonucleotides. Pegg, A.E., Kanugula, S., Edara, S., Pauly, G.T., Moschel, R.C., Goodtzova, K. J. Biol. Chem. (1998) [Pubmed]
  22. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Chakravarti, A., Erkkinen, M.G., Nestler, U., Stupp, R., Mehta, M., Aldape, K., Gilbert, M.R., Black, P.M., Loeffler, J.S. Clin. Cancer Res. (2006) [Pubmed]
  23. Nuclear translocation of mismatch repair proteins MSH2 and MSH6 as a response of cells to alkylating agents. Christmann, M., Kaina, B. J. Biol. Chem. (2000) [Pubmed]
  24. Human liver oxidative metabolism of O6-benzylguanine. Roy, S.K., Korzekwa, K.R., Gonzalez, F.J., Moschel, R.C., Dolan, M.E. Biochem. Pharmacol. (1995) [Pubmed]
  25. O(6)-methylguanine-DNA methyltransferase activity, p53 gene status and BCNU resistance in mouse astrocytes. Nutt, C.L., Loktionova, N.A., Pegg, A.E., Chambers, A.F., Cairncross, J.G. Carcinogenesis (1999) [Pubmed]
  26. Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea. Reese, J.S., Koç, O.N., Lee, K.M., Liu, L., Allay, J.A., Phillips, W.P., Gerson, S.L. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  27. Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. Mitchell, R.B., Moschel, R.C., Dolan, M.E. Cancer Res. (1992) [Pubmed]
  28. Resistance of the human O6-alkylguanine-DNA alkyltransferase containing arginine at codon 160 to inactivation by O6-benzylguanine. Edara, S., Kanugula, S., Goodtzova, K., Pegg, A.E. Cancer Res. (1996) [Pubmed]
WikiGenes - Universities